Dr. Justin Stebbing

Biography

Justin Stebbing, Visiting Professor in Cancer Medicine, specializes in a broad range of malignancies with a focus on immunotherapy and clinical trials for breast, gastrointestinal, and lung cancers. He began his medical studies at Trinity College, Oxford, earning a first-class degree, and continued his training at Johns Hopkins Hospital before returning to the UK to work at the Royal Marsden and St Bartholomew's Hospitals. His early research was during his PhD fellowship, funded by the MRC, examining the interplay between the immune system and cancer, particularly how viruses contribute to immunity in cancer progression and eradication. He was appointed Senior Lecturer at Imperial College London in 2007, became a Professor of Cancer Medicine in 2009, and transitioned to a Visiting Professor role in March 2022, while maintaining an active translational research program. Stemming from his research interests, he has published over 650 peer-reviewed papers in leading journals such as The Lancet and the New England Journal of Medicine. His recent research at Imperial focuses on new therapies for cancer systemic management, employing biomarker-driven approaches, and investigating gene regulation in drug development targeting non-coding RNAs. He is a Fellow of the Royal College of Physicians and the Royal College of Pathologists, and has been involved in numerous international cancer advisory boards. Among his achievements, he played a significant role during the COVID-19 pandemic in discovering the antiviral and anti-inflammatory properties of baricitinib, contributing to its FDA approval.

Research Interests

Experience

Awards